Prezalumab - Amgen/AstraZeneca

Drug Profile

Prezalumab - Amgen/AstraZeneca

Alternative Names: AMG 557/MEDI5872; AMG-557; Anti-B7RP1 MAb; MEDI-5872

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action B7-related protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome
  • No development reported Systemic lupus erythematosus
  • Discontinued Cutaneous lupus erythematosus; Psoriasis

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Australia (SC, Injection)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Denmark (SC, Injection)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Germany (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top